Brief: Anthera Pharmaceuticals Announces Positive Outcome In The Phase 3 Result Clinical Study Of Sollpura
11/12/2017 13:30
Dec 11 (Reuters) - Anthera Pharmaceuticals Inc ANTH.O :
* ANTHERA PHARMACEUTICALS ANNOUNCES POSITIVE OUTCOME OF
INTERIM
FUTILITY ANALYSIS IN THE PHASE 3 RESULT CLINICAL STUDY OF
SOLLPURA
* BASED ON INTERIM FUTILITY ANALYSIS, RESULT STUDY WILL
PROCEED,
AS PLANNED, WITH TOPLINE DATA EXPECTED IN Q1 2018
Source text for Eikon: ID:nGNXOJVWMa
Further company coverage: ANTH.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Anthera Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Micron, Darden, Kroger, American Outdoor
Brief: Anthera Pharma's Board Approves Personnel Reorganization Plan
U.S. STOCKS ON THE MOVE-Anthera, Oclaro, Intel, Broadcom, Netflix, BlueLinx, Micron
U.S. STOCKS ON THE MOVE-Anthera, Oclaro, Intel, Broadcom, BlueLinx, Orexigen, Micron
U.S. STOCKS ON THE MOVE-Anthera, Oclaro, Intel, Broadcom, Orexigen, Goldman